{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:51:45Z","timestamp":1774313505400,"version":"3.50.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee","award":["HB2023117"],"award-info":[{"award-number":["HB2023117"]}]},{"name":"Scientific Research Program of Wuxi Health Commission","award":["Q202307"],"award-info":[{"award-number":["Q202307"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Within the last 10 years, multiple clinical randomized controlled trials in metastatic castration-sensitive prostate cancer patients (mCSPC) have demonstrated that androgen deprivation therapy (ADT) combination therapy is significantly superior to ADT alone. However, there are no guidelines that recommend the best clinical decisions with regard to multi-selective systemic therapy for mCSPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Two independent researchers have conducted a systematic literature search of the Cochrane Central, Web of Science, Clinical Trials. gov and EU Clinical Trial Register databases with a search deadline of July 5, 2022. Hazard Ratio (HR) and 95% confidence intervals were analyzed and extracted for overall and progression-free survival and their subgroups, as well as the number of adverse events. Trial quality was assessed through the Risk of Bias Form and the Newcastle-Ottawa Scale, and systematic reviews and meta-analyses were carried out in strict accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) project.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>8704 patients from 7 studies participated in trials comparing the effectiveness of 4 ADT combination treatments (including ADT\u2005+\u2005docetaxel, ADT\u2005+\u2005abiraterone acetate, ADT\u2005+\u2005enzalutamide, ADT\u2005+\u2005apalutamide) and ADT alone (ADT\u2005+\u2005placebo\/no-treatment). The results suggested that ADT combination therapy was significantly better than ADT alone. Furthermore, based on the patient\u2019s initial clinical characteristics and expected prognosis, we tentatively provided relevant optimal treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>ADT\u2005+\u2005ARAT outperformed ADT\u2005\u00b1\u2005docetaxel in OS\/PFS for mCSPC, with strategies tailored to patient profiles. Future work will leverage advanced analytics and standardized reporting; direct combination trials are critical for precise guidance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000042318","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:01:48Z","timestamp":1760331708000},"page":"e42318","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Systemic treatment of metastatic castration-sensitive prostate cancer: A meta-analysis of efficacy and safety"],"prefix":"10.1097","volume":"104","author":[{"given":"Minhao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Xishan People\u2019s Hospital of Wuxi City, Wuxi, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilin","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Urology, Xishan People\u2019s Hospital of Wuxi City, Wuxi, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongzu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Xishan People\u2019s Hospital of Wuxi City, Wuxi, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4126-485X","authenticated-orcid":false,"given":"Peng","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Urology, Xishan People\u2019s Hospital of Wuxi City, Wuxi, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260113","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260113","article-title":"Cancer Stat Facts SEER. Prostate cancer.","year":"2020"},{"key":"R3-20260113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41391-018-0078-1","article-title":"Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.","volume":"22","author":"Alpajaro","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R4-20260113","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"R5-20260113","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5489\/cuaj.10167","article-title":"Guidelines for the management of castrate-resistant prostate cancer.","volume":"4","author":"Saad","year":"2010","journal-title":"Can Urol Assoc J"},{"key":"R6-20260113","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer.","volume":"378","author":"Sartor","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20260113","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/10898600-000000000-00000","article-title":"Castration-resistant prostate cancer: current and emerging treatment strategies.","volume":"70","author":"Di Lorenzo","year":"2010","journal-title":"Drugs"},{"key":"R8-20260113","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"R9-20260113","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial.","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"R10-20260113","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"R11-20260113","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial.","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"R12-20260113","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"R13-20260113","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"R14-20260113","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"R15-20260113","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer.","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"R16-20260113","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"R17-20260113","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"R18-20260113","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer.","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"R19-20260113","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"R20-20260113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer.","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"R21-20260113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer.","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"R22-20260113","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study.","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"R23-20260113","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/JU.0000000000001363","article-title":"Comparative analysis of genomic alterations across castration sensitive and castration resistant prostate cancer via circulating tumor DNA sequencing.","volume":"205","author":"Fan","year":"2021","journal-title":"J Urol"},{"key":"R24-20260113","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"R25-20260113","doi-asserted-by":"crossref","first-page":"103198","DOI":"10.1016\/j.critrevonc.2020.103198","article-title":"First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings.","volume":"157","author":"Ferro","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"R26-20260113","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.eururo.2019.09.004","article-title":"Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis.","volume":"77","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"key":"R27-20260113","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/JU.0000000000000636","article-title":"New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis.","volume":"203","author":"Marchioni","year":"2020","journal-title":"J Urol"},{"key":"R28-20260113","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.15507","article-title":"Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.","volume":"129","author":"Mori","year":"2022","journal-title":"BJU Int"},{"key":"R29-20260113","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"R30-20260113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporatingsummary time-to-event data into meta-analysis.","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R31-20260113","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R32-20260113","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R33-20260113","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"R34-20260113","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrd4068","article-title":"Advances in prostate cancer treatment.","volume":"12","author":"Trewartha","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"R35-20260113","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrurol.2012.237","article-title":"Adaptation or selection\u2014mechanisms of castration-resistant prostate cancer.","volume":"10","author":"Zong","year":"2013","journal-title":"Nat Rev Urol"},{"key":"R36-20260113","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019.","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"key":"R37-20260113","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","article-title":"The effect of F877L and T878A mutations on androgen receptor response to enzalutamide.","volume":"15","author":"Prekovic","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"R38-20260113","doi-asserted-by":"crossref","first-page":"e1033","DOI":"10.1002\/cpz1.1033","article-title":"Developing a novel enzalutamide-resistant prostate cancer model via AR F877L mutation in LNCaP cells.","volume":"4","author":"Wang","year":"2024","journal-title":"Curr Protoc"},{"key":"R39-20260113","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acs.jmedchem.0c01563","article-title":"Discovery of JNJ-63576253: a clinical stage androgen receptor antagonist for F877L mutant and wild-type castration-resistant prostate cancer (mCRPC).","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"key":"R40-20260113","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"R41-20260113","doi-asserted-by":"crossref","first-page":"e2300330","DOI":"10.1200\/PO.23.00330","article-title":"Prevalence and spectrum of AR ligand-binding domain mutations detected in circulating-tumor DNA across disease states in men with metastatic castration-resistant prostate cancer.","volume":"8","author":"Antonarakis","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"R42-20260113","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies.","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"R43-20260113","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:00:41Z","timestamp":1768334441000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":43,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042318","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"2024-10-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}